Ototoxicity monitoring in children treated with platinum chemotherapy

References

• Abujamra, A.L., Escosteguy, J.R., Dall'Igna, C., Manica, D., Cigana, L.F., et al. 2013. The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy. Pediatr Blood Cancer, 60, 474–478.
   PubMed Web of Science ®Google Scholar
• Al-Noury K. 2011. Distortion product otoacoustic emission for the screening of cochlear damage in children treated with cisplatin. Laryngoscope, 121, 1081–1084.
   PubMed Web of Science ®Google Scholar
• Bass, J.K., Huang, J., Onar-Thomas, A., Chang, K.W., Bhagat, S.P., et al. 2014. Concordance between the Chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatr Blood Cancer, 61, 601–605.
   PubMed Web of Science ®Google Scholar
• Bass, J.K., Hua, C.H., Huang, J., Onar-Thomas, A., Ness, K.K., et al. 2016. Hearing Loss in patients who received cranial radiation therapy for childhood cancer. J Clin Oncol, 34, 1248–1255.
   PubMed Web of Science ®Google Scholar
• Beahan, N., Dei, J., Driscoll, C., Charles, B. & Khan, A. 2012. High-frequency pure-tone audiometry in children: a test-retest reliability study relative to ototoxic criteria. Ear Hear, 33, 104–111.
   PubMed Web of Science ®Google Scholar
• Bench, J., Kowal, A. & Bamford, J. 1979. The BKB (Bamford-Kowal-Bench) sentence lists for partially-hearing children. Br J Audiol, 13, 108–112.
   PubMedGoogle Scholar
• Bertolini, P., Lassalle, M., Mercler, G., Raguin, M.A., Izzi, G., et al. 2004. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol, 26, 649–655.
   Web of Science ®Google Scholar
• Bhagat, S.P., Bass, J.K., White, S.T., Qaddoumi, I., Wilson, M.W., et al. 2010. Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma. Int J Pediatr Otorhinolaryngol, 74, 1156–1163.
   PubMed Web of Science ®Google Scholar
• Brinkman, R.M., Bass, J.K., Li, Z., Ness, K.K., Gajjar, A., et al. 2015. Treatment-induced hearing loss and adult social outcomes in survivors of childhood CNS and non-CNS solid tumors: Results from the St. Jude Lifetime Cohort Study. Cancer, 121, 4053–4061.
   PubMed Web of Science ®Google Scholar
• Brock, P.R., Knight, K.R., Freyer, D.R., Campbell, K.C., Steyger, P.S., et al. 2012. Platinum-induced ototoxicity in children: A consensus review on mechanisms, predisposition, and protection, including a New International Society of Pediatric Oncology Boston Ototoxicity Scale. J Clin Oncol, 30, 2408–2417.
   PubMed Web of Science ®Google Scholar
• Carleton, B.C., Ross, C.J., Pussegoda, K., Bhavsar, A.P., Visscher, H., et al. 2014. Genetic markers of cisplatin-induced hearing loss in children. Clin Pharmacol Ther, 96, 296–298.
   PubMed Web of Science ®Google Scholar
• Chang, K.W. & Chinosornvatana, N. 2010. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol, 28, 1788–1795.
   PubMed Web of Science ®Google Scholar
• Children’s Oncology Group, 2006. Long-term follow up guidelines for survivors of childhood, adolescent, and young adult cancers. Retrieved from: October 20, 2016: http://www.survivorshipguidelines.org/.
   Google Scholar
• Choeyprasert, W., Sawangpanich, R., Lertsukprasert, K., Udomsubpayakul, U., Songdej, D., et al. 2013. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms. J Pediatr Hematol Oncol, 35, e138–e143.
   PubMed Web of Science ®Google Scholar
• Coradini, P.P., Cigana, L., Selistre, S.G., Rosito, L.S. & Brunetto, A.L. 2007. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol, 29, 355–360.
   PubMed Web of Science ®Google Scholar
• DeBacker, J.R., Harrison, R.T. & Bielefield, E.C. 2017. Long-term synergistic interaction of cisplatin- and noise-induced hearing losses. Ear Hear, 38, 282–291.
   PubMed Web of Science ®Google Scholar
• Dhooge, I., Dhooge, C., Geukens, S., De Clerck, B., De Vel, E., et al. 2006. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives. Int J Audiol, 45, 337–343.
   PubMed Web of Science ®Google Scholar
• Einarsson, E.J., Petersen, H., Wiebe, T., Fransson, P.A., Grenner, J., et al. 2010. Long term hearing degeneration after platinum-based chemotherapy in childhood. Int J Audiol, 49, 765–771.
   PubMed Web of Science ®Google Scholar
• Einarsson, E.J., Petersen, H., Wiebe, T., Fransson, P.A., Magnusson, M., et al. 2011. Severe difficulties with word recognition in noise after platinum chemotherapy in childhood, and improvements with open-fitting hearing-aids. Int J Audiol, 50, 642–651.
   PubMed Web of Science ®Google Scholar
• Fausti, S.A., Frey, R.H., Henry, J.A., Olson, D.J. & Schaffer, H.I. 1992. Early detection of ototoxicity using high-frequency, tone-burst-evoked auditory brainstem responses. J Am Acad Audiol, 3, 397–404.
   PubMedGoogle Scholar
• Frank T. 2001. High frequency (8-16 kHz) reference thresholds and intra-subject threshold variability relative to ototoxicity criteria using a Sennheiser HDA 200 earphone. Ear Hear, 22, 161–168.
   PubMed Web of Science ®Google Scholar
• Gardner, H.J. 1971. Application of a high-frequency consonant discrimination word list in hearing-aid evaluation. J Speech Hear Disord, 36, 354–355.
   PubMedGoogle Scholar
• Glista, D. & Scollie, S. 2012. Development and evaluation of an English language measure of detection of word-final plurality markers: the University of Western Ontario Plurals Test. Am J Audiol, 21, 76–81.
   PubMed Web of Science ®Google Scholar
• Grewal, S., Merchant, T., Reymond, R., Hodge CM., et al. 2010. Auditory late effects of childhood cancer therapy: A report from the Children's Oncology Group. Pediatrics, 125, e938–e950.
   PubMed Web of Science ®Google Scholar
• Gurney, J.G., Tersak, J.M., Ness, K.K., Landier, W., Matthay, K.K., et al. 2007. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children’s Oncology Group. Pediatrics, 120, 1229–1236.
   PubMed Web of Science ®Google Scholar
• Killion, M., Niquette, P., Gudmundsen, G., Revit, L. & Banerjee, S. 2004. Development of a quick speech-in-noise test for measuring signal-to-noise ratio loss in normal-hearing and hearing-impaired listeners. J Acoust Soc Am, 116, 2395–2405.
   PubMed Web of Science ®Google Scholar
• Knight, K.R., Kraemer, D.F. & Neuwelt, E.A. 2005. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol, 23, 8588–8596.
   PubMed Web of Science ®Google Scholar
• Knight, K.R., Kraemer, D.F., Winter, C. & Neuwelt, E.A. 2007. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol, 25, 1190–1195.
   PubMed Web of Science ®Google Scholar
• Kolinsky, D.C., Hayashi, S.S., Karzon, R., Mao, J. & Hayashi, R.J. 2013. Late onset hearing loss: a significant complication of cancer survivors treated with cisplatin containing chemotherapy regimens. J Pediatr Hematol Oncol, 32, 119–123.
   Web of Science ®Google Scholar
• Landier, W., Knight, K., Wong, F.L., Lee, J., Thomas, O., et al. 2014. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales-a report from the Children's Oncology Group. J Clin Oncol, 32, 527–534.
   PubMed Web of Science ®Google Scholar
• Lee, J.W., Pussegoda, K., Rassekh, S.R., Monzon, J.G., Liu, G., et al. 2016. Clinical practice recommendations for the management and prevention of cisplatin-induced hearing loss using pharmacogenetic markers. Ther Drug Monit, 38, 423–431.
   PubMed Web of Science ®Google Scholar
• Lewis, M.J., DuBois, S.G., Fligor, B., Li, X., Goorin, A., et al. 2009. Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer, 52, 387–391.
   PubMed Web of Science ®Google Scholar
• Li, Y., Womer, R.B. & Silber, J.H. 2004. Predicting cisplatin ototoxicity in children: The influence of age and the cumulative dose. Eur J Cancer, 40, 2445–2451.
   PubMed Web of Science ®Google Scholar
• Ling D. 1989. Foundations of Spoken Language for Hearing-Impaired Children. Washington, DC: Alexander Graham Bell Association for the Deaf, Inc.
   Google Scholar
• Parsons, S.K., Neault, M.W., Lehmann, L.E., Brennan, L.L., Eickhoff, C.E., et al. 1998. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant, 22, 669–674.
   PubMed Web of Science ®Google Scholar
• Peleva, E., Emami, N., Alzahrani, M., Bezdjian, A., Gurberg, J., et al. 2014. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec. Pediatr Blood Cancer, 61, 2012–2017.
   PubMed Web of Science ®Google Scholar
• Punnett, A., Bliss, B., Dupuis, L.L., Abolell, M., Doyle, J., et al. 2004. Ototoxicity following pediatric hematopoietic stem cell transplantation: a prospective cohort study. Pediatr Blood Cancer, 42, 598–603.
   PubMed Web of Science ®Google Scholar
• Pussegoda, K., Ross, C.J., Visscher, H., Yazdanpanah, M., Brooks, B., et al. 2013. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther, 94, 243–251.
   PubMed Web of Science ®Google Scholar
• Qaddoumi, I., Bass, J.K., Wu, J., Billups, C.A., Wozniak, A.W., et al. 2012. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol, 30, 1034–1041.
   PubMed Web of Science ®Google Scholar
• Ramírez-Camacho, R., García-Berrocal, J.R., Buján, J., Martín-Marero, A. & Trinidad, A. 2004. Supporting cells as a target of cisplatin-induced inner ear damage: therapeutic implications. Laryngoscope, 114, 533–537.
   PubMed Web of Science ®Google Scholar
• Rednam, S., Scheurer, M.E., Adesina, A., Lau, C.C. & Okcu, M.F. 2013. Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma. Pediatr Blood Cancer, 60, 593–598.
   PubMed Web of Science ®Google Scholar
• Ross, C.J., Katzov-Eckert, H., Dubé, M.P., Brooks, B., Rassekh, S.R., et al. 2009. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet, 41, 1345–1349.
   PubMed Web of Science ®Google Scholar
• Rybak, L.P., Whitworth, C.A., Mukherjea, D. & Ramkumar, V. 2007. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res, 226, 157–167.
   PubMed Web of Science ®Google Scholar
• Sininger, Y.S., Grimes, A. & Christensen, E. 2010. Auditory development in early amplified children: factors influencing auditory-based communication outcomes in children with hearing loss. Ear Hear, 31, 166–185.
   PubMed Web of Science ®Google Scholar
• Schreiber, J.E., Gurney, J.G., Palmer, S.L., Bass, J.K., Wang, M., et al. 2014. Examination of risk factors for intellectual and academic outcomes following treatment for pediatric medulloblastoma. Neuro-oncology, 16, 1129–1136.
   PubMed Web of Science ®Google Scholar
• Summers, V., Makashay, M.J., Theodoroff, S.M. & Leek, M.R. 2013. Suprathreshold auditory processing and speech perception in noise: hearing-impaired and normal-hearing listeners. J Am Acad Audiol, 24, 274–292.
   PubMed Web of Science ®Google Scholar
• van As, J.W., van den Berg, H. & van Dalen, E.C. 2016. Platinum-induced hearing loss after treatment for childhood cancer. Cochrane Database Syst Rev, 3(8):CD010181. doi: 10.1002/14651858.CD010181.pub2.
   Web of Science ®Google Scholar
• Warrier, R., Chauhan, A., Davluri, M., Tedesco, S.L., Nadell, J., et al. 2012. Cisplatin and cranial irradiation-related hearing loss in children. Ochsner J, 12, 191–196.
   PubMedGoogle Scholar
• Williams, G.B., Kun, L.E., Thompson, J.W., Gould, H.J. & Stocks, R.M. 2005. Hearing loss as a late complication of radiotherapy in children with brain tumors. Ann Otol Rhinol Laryngol, 114, 328–331.
   PubMed Web of Science ®Google Scholar
• Xu, H., Robinson, G.W., Huang, J., Lim, J.Y., Zhang, H., et al. 2015. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet, 47, 263–266.
   PubMed Web of Science ®Google Scholar
• Yancey, A., Harris, M.S., Egbelakin, A., Gilbert, J., Pisoni, D.B. & Renbarger, J. 2012. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer, 59, 144–148.
   PubMed Web of Science ®Google Scholar